National Institute for Health and Care Excellence

10/06/2026

NICE healthtech director Thomas Slater is on the panel at , exploring how innovation moves from research to real-world NHS adoption.

The session will explore how commitments in the 10 Year Health Plan and Life Sciences Sector Plan can be realised, and how all parts of the innovation ecosystem can work together to deliver better outcomes for patients.

👉Developing or adopting healthtech? Explore support: https://www.nice.org.uk/what-nice-does/our-guidance/about-healthtech-guidance

09/06/2026

This Diabetes Week 2026, we're sharing Aleix's story.

Managing her type 1 diabetes meant constant calculations, frequent blood sugar checks and saying no to activities she loved.

Then she got a hybrid closed loop device. The difference was immediate: less worry, better sleep and the freedom to truly enjoy life.

📈 Since we recommended this tech for eligible patients, NHS uptake for children and young people (a priority group) has risen from 36% to 73%.

This successful rollout is the model we want to replicate – getting life-changing medtech, diagnostics and digital products to patients who need them while reducing pressure on frontline NHS services.

👉Developing or adopting healthtech? Explore support: https://www.nice.org.uk/what-nice-does/our-guidance/about-healthtech-guidance



https://youtu.be/q2K18qy825o?si=uhcXx2pfOIF_rRd-

Aleix shares how a hybrid closed loop device transformed her type 1...

08/06/2026

This Diabetes Week 2026, we're sharing Aleix's story.

Managing her type 1 diabetes meant constant calculations, frequent blood sugar checks and saying no to activities she loved.

Then she got a hybrid closed loop device. The difference was immediate: less worry, better sleep and the freedom to truly enjoy life.

📈 Since we recommended this tech for eligible patients, NHS uptake for children and young people (a priority group) has risen from 36% to 73%.

This successful rollout is the model we want to replicate – getting life-changing medtech, diagnostics and digital products to patients who need them while reducing pressure on frontline NHS services.

👉Developing or adopting healthtech? Explore support: about healthtech guidance | nice

Aleix shares how a hybrid closed loop device transformed her type 1...

22/05/2026

1 in 7 people in the UK live with migraine, but for years many had exhausted every available treatment with little relief.

That's changing.

Since NICE recommended atogepant and rimegepant, the first migraine-prevention tablets of their kind, prescriptions have more than tripled in a year. In 2025, 22,800 people received these medicines through their GP alone.

Migraines can last days, affect work, mental health and relationships, and cost the UK economy up to £9 billion a year. These tablets work differently from older preventative treatments, targeting the chemical directly associated with migraine attacks.

🔗 Read the data story: https://www.nice.org.uk/news/articles/more-than-20-000-people-benefitting-from-innovative-migraine-pills-recommended-by-nice?utm_medium=organic&utm_source=facebook&utm_campaign=migrane_date&utm_content=graphic

19/05/2026

"No one can understand the process as well as a patient."

After surviving a heart attack at 38, Debra joined a NICE committee as a lay member and used her lived experience to help shape our guidance on digital platforms for cardiac rehabilitation, ensuring future patients can recover at home.

At NICE, the patient perspective sits at the heart of every decision we make. Debra's story is a powerful example of why the voices of patients and lay members are so important in developing guidance that truly reflects what matters to people.

Read Debra's story here 🔗 https://indepth.nice.org.uk/from-patient-to-changemaker/index.html

13/05/2026

Bringing your baby home is one of the moments new parents look forward to most.

But for families whose newborns need precautionary antibiotics, that can mean an unexpectedly longer stay in hospital.

New NICE guidance published today means that could change.

Where a baby is born after 35 weeks, is stable, feeding well and responding to treatment, they may now be able to switch from an intravenous drip to a simple liquid antibiotic and complete their course at home, with full support from their neonatal team, including training for parents and at least two follow-up appointments after leaving hospital.

The safety of this approach has been tested across nine NHS sites in England, and the evidence is clear: babies do just as well at home as in hospital. And for many families, being able to settle in at home makes a meaningful difference to those early days together.

🔗 Read the updated guidance: https://www.nice.org.uk/news/articles/nice-updates-neonatal-infection-guidance-to-allow-home-antibiotic-treatment-for-some-babies?utm_medium=organic&utm_source=facebook&utm_campaign=neonatal_infection_13may&utm_content=graphic

05/05/2026

"My treatment has completely transformed my life.”

In Dudley, an asthma clinic is catching people before they reach crisis point, diagnosing faster and making sure patients have the right treatment from the start.

One child had missed 80 days of school because of chest problems. After one clinic visit, they had a diagnosis and a plan.

Read the full story: https://indepth.nice.org.uk/my-treatment-has-completely-transformed-my-life/index.html

05/05/2026

Lee Newton-Proctor has had asthma since he was 3 years old. By his late thirties, he'd been hospitalised 18 times and was getting through up to 18 blue inhalers a year.

Then his doctor recommended a combination inhaler, one that treats the underlying inflammation, not just the symptoms. Now he exercises regularly and rarely thinks about his asthma.

Lee isn't alone. For the first time, more people in England are managing asthma with combination inhalers recommended by NICE, than blue inhalers alone. Between October and December 2025, 1.09 million people used AIR or MART therapy, up 63% in a year.

New guidelines from NICE, the British Thoracic Society and the Scottish Intercollegiate Guidelines Network (SIGN) recommend combination inhalers for most people with asthma aged 12 and over.

If you or someone you know relies on a blue inhaler, it's worth having a conversation with your GP.

https://www.nice.org.uk/news/articles/-i-no-longer-feel-asthmatic-more-than-a-million-people-now-using-new-style-inhalers?utm_medium=organic&utm_source=facebook&utm_campaign=asthma_data_story_5may&utm_content=graphic

28/04/2026

Bowel cancer is the UK's second biggest cause of cancer death — but a simple home test is changing that.

The faecal immunochemical test (FIT) is helping people get faster answers, preventing thousands of unnecessary hospital referrals, all while keeping cancer detection rates stable.
That means less waiting, less worry, and more NHS capacity for those who need it most.
Find out how FIT is transforming bowel cancer diagnosis: https://www.nice.org.uk/news/articles/simple-home-test-prevents-thousands-of-unnecessary-bowel-cancer-referrals?utm_medium=organic&utm_source=facebook&utm_campaign=fit_data&utm_content=graphic

01/04/2026

We've recommended semaglutide (Wegovy) on the NHS to protect heart patients from a second heart attack or stroke.

Here's what you need to know: https://www.nice.org.uk/news/articles/semaglutide-injection-to-help-prevent-heart-attacks-and-strokes?utm_medium=organic&utm_source=facebook&utm_campaign=semaglutide_010426&utm_content=graphic